Stock Analysts

BioMarin Q2 Loss Narrower than Expected, Revenue Guidance Up

BioMarin Pharmaceutical ’s ( BMRN ) second quarter 2014 loss on an adjusted basis of 19 cents per share was much narrower than the Zacks Consensus Estimate of a loss of 42 cents but wider than the year-ago loss of 16 cents per share. The narrower-than-expected loss was primarily due to higher-than-expected revenues. […]

Mergers & Acquisitions

Canaccord Genuity expands equity research group with addition to its US biotechnology practice

Canaccord Genuity expands equity research group with addition to its US biotechnology practice PR Newswire NEW YORK, July 31, 2014 NEW YORK , July 31, 2014 /PRNewswire/ – Canaccord Genuity is pleased to announce that Marko Kozul , M.D. has agreed to join its Equity Research team as a Managing Director covering biotechnology companies. “The addition of Dr. […]

Stock Analysts

Tesla (TSLA), LinkedIn (LNKD) Beat Q2 Estimates on Bigger Sales

Both electric car maker Tesla Motors ( TSLA ) and social media firm LinkedIn ( LNKD ) reported Q2 earnings after the bell Thursday, and both representatives of the 21st century economy outperformed expectations on both top and bottom lines. Tesla posted a loss of 16 cents per share (accounting for stock-based compensation) on revenues of $858 million in the quarter. LinkedIn earnings reached 4 cents per share on $534 million […]

Stock Analysts

Expedia Books Earnings Beats!

Expedia Books Earnings Beats! Expedia Inc ( EXPE ) reported Q2 earnings after the bell today. EPS crushed the Zacks Consensus Estimate of $0.68, by posting an EPS of $1.03. Revenues also beat the Zacks Consensus Revenue Estimate of $1.444 billion, but announcing Revenues of $1.49 billion […]